A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with CD4 count <= 200 cells/mm3.
PCP prophylaxis with aerosolized pentamidine in patients with CD4 count > 200 cells/mm3, only at the discretion of the treating physician.
Patients must have:
Absolute CD4 count of 150 - 500 cells/mm3.
At least 6 months of prior zidovudine therapy.
No active opportunistic infection requiring ongoing therapy.
Life expectancy of at least 6 months.
Patients with the following symptoms or conditions are excluded:
Neoplasm other than basal cell carcinoma of the skin.
Clinically significant cardiac disease.
Abnormal neurological status by a standardized assessment including strength, reflex testing, and sensory testing.
Unwilling to comply with protocol requirements.
Patients with the following prior conditions are excluded:
History of myocardial infarction or arrhythmias.
Excluded within 2 weeks prior to study entry:
Antiretroviral agent or interferon.
Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic agents, or other drugs that can cause neutropenia or significant nephrotoxicity.
Rifampin or rifampin derivatives.
At least 6 months of prior zidovudine. Active drug or alcohol abuse.
Busch HW, Christensen S, Reichelt D, Jahn S, Zidek W. Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO). Int Conf AIDS. 1994 Aug 7-12;10(1):204 (abstract no PB0245)
Kahn JO, McGrath MS, Ching OM, Kuhne FW. A single center, phase 2 study evaluating the effects of WF10. Int Conf AIDS. 1998;12:349 (abstract no 22423)